imtoken官方版钱包下载|strc

Sarcos Technology and Robotics Corporation (STRC) Stock Price, News, Quote & History - Yahoo Finance

os Technology and Robotics Corporation (STRC) Stock Price, News, Quote & History - Yahoo FinanceHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...Yahoo FinanceSearchSkip to NavigationSkip to Main ContentSkip to Related ContentSign inMailSign in to view your mailWatchlistsMy PortfolioMarketsNewsVideosScreenersPersonal FinanceCryptoSectorsContact Us

Advertisement

U.S. markets closedS&P 5005,175.27+57.33(+1.12%)Dow 3039,005.49+235.83(+0.61%)Nasdaq16,265.64+246.36(+1.54%)Russell 20002,065.48-0.40(-0.02%)Crude Oil78.04+0.11(+0.14%)Gold2,163.80-24.80(-1.13%)Sarcos Technology and Robotics Corporation (STRC)NasdaqGM - NasdaqGM Real Time Price. Currency in USDFollow1.4800-0.1400 (-8.64%)At close: 04:00PM EDT SummaryChartConversationsStatisticsHistorical DataProfileFinancialsAnalysisOptionsHoldersSustainability1d5d1m6mYTD1y5yMaxFull screenTrade prices are not sourced from all marketsPrevious Close1.6200Open1.6200Bid1.4600 x 1000Ask1.8600 x 3100Day's Range1.4200 - 1.620052 Week Range0.3980 - 3.2500Volume329,906Avg. Volume773,778Market Cap38.299MBeta (5Y Monthly)3.18PE Ratio (TTM)N/AEPS (TTM)-4.5100Earnings DateMar 14, 2024 - Mar 18, 2024Forward Dividend & YieldN/A (N/A)Ex-Dividend DateN/A1y Target Est1.00AllNewsPress ReleasesSEC FilingsBusiness WireSarcos Welcomes Back Co-Founder and Former CEO Ben Wolff to Lead Company Following Pivot to Industrial AI Software FocusSALT LAKE CITY, January 17, 2024--Sarcos Technology and Robotics Corporation ("Sarcos") (NASDAQ: STRC) (NASDAQ: STRCW) is pleased to announce that effective as of February 23, 2024, the company’s co-founder and former CEO, Ben Wolff, will resume the role of president and CEO as the Company pursues its next phase of innovation and growth, with a concerted focus on commercializing and deploying the robotic artificial intelligence (AI) and machine learning (ML) software platform that the Company beSimply Wall St.What You Need To Know About The Sarcos Technology and Robotics Corporation (NASDAQ:STRC) Analyst Downgrade TodayMarket forces rained on the parade of Sarcos Technology and Robotics Corporation ( NASDAQ:STRC ) shareholders today...Insider MonkeySarcos Technology and Robotics Corporation (NASDAQ:STRC) Q3 2023 Earnings Call TranscriptSarcos Technology and Robotics Corporation (NASDAQ:STRC) Q3 2023 Earnings Call Transcript November 14, 2023 Sarcos Technology and Robotics Corporation misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.59. Operator: Good day, and thank you for standing by. Welcome to the Q3 2023 Sarcos Technology and Robotics Corporation Earnings Conference Call. At this […]

Advertisement

Advertisement

Advertisement

Data DisclaimerHelpSuggestionsTermsandPrivacy PolicyPrivacy DashboardAbout Our AdsSitemap© 2024 Yahoo. All rights reserved.

Facebook

Facebook

Sarcos Technology and Robotics Corp (STRC) Stock Price & News - Google Finance

os Technology and Robotics Corp (STRC) Stock Price & News - Google FinanceFinanceSign inFinanceFinancefinance_modeHomemanage_searchMarket trendsPortfoliosaddCreate portfolioWatchlistsaddCreate watchlistsettingsSettingsfeedbackSend feedbackMarketsUSEuropeAsiaCurrenciesCryptoFuturesNikkei 22538,797.51-0.059%-22.98Nikkei 22538,797.510.059%SSE3,055.94-0.41%-12.52SSE3,055.940.41%HSI17,093.50+3.05%+505.93HSI17,093.503.05%SENSEX73,667.96+0.22%+165.32SENSEX73,667.960.22%NIFTY 5022,335.70+0.014%+3.05NIFTY 5022,335.700.014%HomeSTRC • NASDAQSarcos Technology and Robotics CorpFollowShare$1.48Mar 12, 4:30:00 PM GMT-4 · USD · NASDAQ · Disclaimer1D5D1M6MYTD1Y5YMAXinsightsKey eventsKey events shows relevant news articles on days with large price movementsKey eventsKey events shows relevant news articles on days with large price movementsKey eventsarrow_forward_iosKey events shows relevant news articles on days with large price movementsNo dataclosesearchCompare toBigBear.ai Holdings Inc$2.33BBAI3.32%Vincerx Pharma Inc$6.45VINC19.98%Airship AI Holdings Inc$7.65AISP11.35%Enviva Inc$0.60EVA9.71%Renalytix PLC$0.91RNLX20.25%Cardiff Oncology Inc$4.48CRDF10.89%Beyondspring Inc$3.01BYSI0.33%Envoy Medical Inc$7.60COCH1.33%Jin Medical International Ltd$6.44ZJYL6.40%Femasys Inc$1.91FEMY2.69%In the newsInvestorPlace2 weeks ago3 Millionaire-Maker Robotics Stocks to Buy in February 2024FinancialsIncome StatementQuarterlyAnnualDec 2023Sep 2023Jun 2023Mar 2023Dec 2022RevenueNet income(USD)Dec 2023infoFiscal Q4 2023 ended 12/31/23.Y/Y changeRevenueThe total amount of income generated by the sale of goods or services related to the company's primary operations746.00K-87.81%Operating expenseRepresents the total incurred expenses through normal operations15.09M-43.38%Net incomeCompany’s earnings for a period net of operating costs, taxes, and interest-36.48M60.49%Net profit marginMeasures how much net income or profit is generated as a percentage of revenue.-4.89K-224.22%Earnings per shareRepresents the company's profit divided by the outstanding shares of its common stock.——EBITDAEarnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances-14.78M39.33%Effective tax rateThe percent of their income that a corporation pays in taxes-0.01%—Balance SheetQuarterlyAnnualDec 2023Sep 2023Jun 2023Mar 2023Dec 2022Total assetsTotal liabilities(USD)Dec 2023infoFiscal Q4 2023 ended 12/31/23.Y/Y changeCash and short-term investmentsInvestments that are relatively liquid and have maturities between 3 months and one year39.09M-65.86%Total assetsThe total amount of assets owned by a company60.43M-63.95%Total liabilitiesSum of the combined debts a company owes19.52M-15.77%Total equityThe value of subtracting the total liabilities from the total assets of a company40.90M—Shares outstandingTotal number of common shares outstanding as of the latest date disclosed in a financial filing25.88M—Price to bookA ratio used to determine if a company’s market value is in line with the value of its assets less liabilities and preferred stock1.03—Return on assetsA financial ratio that shows a company’s profitability compared to its assets-49.47%—Return on capitalCompany’s return above the average cost it pays for its debt and equity capital-54.30%—Cash FlowQuarterlyAnnualDec 2023Sep 2023Jun 2023Mar 2023Dec 2022Net change in cash(USD)Dec 2023infoFiscal Q4 2023 ended 12/31/23.Y/Y changeNet incomeCompany’s earnings for a period net of operating costs, taxes, and interest-36.48M60.49%Cash from operationsNet cash used or generated for core business activities-16.50M21.23%Cash from investingNet cash used or generated in investing activities such as purchasing assets4.34M-89.26%Cash from financingNet cash used or generated in financing activities such as dividend payments and loans-11.00K97.32%Net change in cashThe amount by which a company's cash balance increases or decreases in an accounting period-12.17M-163.96%Free cash flowAmount of cash a business has after it has met its financial obligations such as debt and outstanding payments-6.75M47.33%StockOwnership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock ownedUS listed securityListed on NASDAQUS headquarteredHeadquartered in Salt Lake City, Utah, United StatesPrevious closeThe last closing price$1.62Day rangeThe range between the high and low prices over the past day$1.42 - $1.62Year rangeThe range between the high and low prices over the past 52 weeks$0.40 - $3.25Market capA valuation method that multiplies the price of a company's stock by the total number of outstanding shares.38.33M USDAvg VolumeThe average number of shares traded each day over the past 30 days1.47MP/E ratioThe ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks-Dividend yieldThe ratio of annual dividend to current share price that estimates the dividend return of a stock-Primary exchangeListed exchange for this securityNASDAQAboutSarcos Technology and Robotics Corporation is an American company that was known for most of its existence as a developer of robots. In 2023, Sarcos "pivoted" to become a developer of artificial-intelligence software, specifically for robotic applications. This pivot was accompanied by a cessation of all operations involving hardware, such that what was once primarily a robotics-research and manufacturing company is now strictly a developer of AI software.

For most of its history, Sarcos specialized in creating robotic systems. The company's work from this era was found in a wide variety of applications, including entertainment animatronics such as the life-sized robotic dinosaurs of Jurassic Park: The Ride of Universal Studios Hollywood, robotic displays, NASA space-suit-testing equipment, prosthetic limbs, and even MEMS actuators and sensors. WikipediaCEOBenjamin G WolffFounded2020HeadquartersSalt Lake City, UtahUnited StatesWebsitesarcos.comEmployees70Discover moreYou may be interested ininfoThis list is generated from recent searches, followed securities, and other activity. Learn moreAll data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn moreIndexS&P 5005,175.271.12%add_circle_outlineIndexDow Jones Industrial Average39,005.490.61%add_circle_outlinePHParker-Hannifin Corp$538.280.42%add_circle_outlineTELTE Connectivity Ltd$140.540.35%add_circle_outlineMRCMRC Global Inc$12.150.25%add_circle_outlineGLOClough Global Opportunities Fund$5.020.40%add_circle_outlineSMSM Energy Co$45.720.79%add_circle_outlineTSLATesla Inc$177.540.13%add_circle_outlineAAPLApple Inc$173.230.28%add_circle_outlineGOOGAlphabet Inc Class C$139.620.49%add_circle_outlineFFord Motor Co$12.110.083%add_circle_outlineMACMacerich Co$15.900.25%add_circle_outlineAPAmpco-Pittsburgh Corp$2.501.57%add_circle_outlineARAntero Resources Corp$26.180.53%add_circle_outlineFGENFibroGen Inc$1.8910.53%add_circle_outlineMETAMeta Platforms Inc$499.753.34%add_circle_outlineBABAAlibaba Group Holding Ltd - ADR$76.061.59%add_circle_outlineNFLXNetflix Inc$611.081.69%add_circle_outlinePeople also search forBBAIBigBear.ai Holdings Inc$2.333.32%add_circle_outlineVINCVincerx Pharma Inc$6.4519.98%add_circle_outlineAISPAirship AI Holdings Inc$7.6511.35%add_circle_outlineEVAEnviva Inc$0.609.71%add_circle_outlineRNLXRenalytix PLC$0.9120.25%add_circle_outlineCRDFCardiff Oncology Inc$4.4810.89%add_circle_outlineBYSIBeyondspring Inc$3.010.33%add_circle_outlineCOCHEnvoy Medical Inc$7.601.33%add_circle_outlineZJYLJin Medical International Ltd$6.446.40%add_circle_outlineFEMYFemasys Inc$1.912.69%add_circle_outlineCMAXCaremax Inc$6.544.39%add_circle_outlineJANXJanux Therapeutics Inc$38.832.85%add_circle_outlineVKTXViking Therapeutics Inc$67.105.77%add_circle_outlineOCEAOcean Biomedical Inc$3.8513.87%add_circle_outlineHTOOFusion Fuel Green PLC$1.640.61%add_circle_outlineSWINSolowin Holdings Ltd$29.104.78%add_circle_outlineREALRealReal Inc$3.360.59%add_circle_outlinePHUNPhunware Inc$10.400.19%add_circle_outlineHelpSend feedbackPrivacyTermsDisclaimerSearchClear searchClose searchGoogle appsMain m-1.4

%�쏢

5 0 obj

<>

stream

x��[[wܶ~�_��dO�%��&%���N��C��!�۩-َ�����?�p��`AJ+'�4~a���s��
�öm߶�_z�x����n��Mx�}�0>||���1���������t��-o�Vn�?m��Z�Z�ζV4VY��Zָ���<���;�X���5kZm9���;'ɥ�՗5o�Nv���N��z�&ZwգZ6�i����1qN�LuV+�7���|n��s+]��r²�t�͓a���瓰/%;��'aFf:�%�$�RV�)���ׯ������Y�veE'���X%��3?��j������ك�-S�ՃAZ�a��_gmx#�Aܠ�������7�?=w��6�1kL���ɦ�B��߇T�Un��f��~�wn!ˍ��{Q���֋v�mI���ȿ�f�QBVo��H��GX���ojݘV��2�k�.�Bf1$�K���r�r��.BL�U�j�5L��E�7��4\3i�n_�̴'\(̵gD�G�Q�1�����_RC����\Q��T�Xϰ���kBv����������f�E���G7��}3JFo�Guѿ����x��6q����A[��\�~����]�s��(���n D*�-��R���p�?¨o`�[���}/�~s�����%_��rv7����)���:�r�ǿ ]fE�7s�d%s�ƎD�_�xr"ՔlX��7�4ބ=r��HnG�=��b<�&�A�{�g������Y�j�m��^N-`�W0�����"��J�[�`�'�֥��R߃]AT�p�bQ�s�o:��>���r+����KxD�!/<'g8��67O��vsYJ@�R����0��u��\�,*� �]�i���D���:Ӵ�,0�5��#���3&���8r �!���R��;!�7I�<���&��d�mC"�w��=�Ac֑���n�@�� d�)� ���k碗�o��?�7�� �����

)�%s���k���D�)�aT)�H��^�2�E��oEjQ��i�Ϧ'��>��>��X>a�ޛ>�qG@�Mn3#�� � �c��q �'tP�����*���.ԣ��TPy��.X[#��7p����F���h� ����Bi�(�{�m���<1K�g��=��;�e��=0�3�'0�qܕ��I���Pَ��I�*#�B$��Y

��d�?���������b�)wF>��L�h��~
(="��e���z�R��Bv���9��:

����U~z�b�Y�l��b,âР9�L�-S}*���[�-l��ށ�N|�?���t;N�x���N�B�LJ.� >dh�g��&�x�A�wn�:�= �"�%cq�o��D�
��D~$�����nAg_��nDR���%��L�y>��Y6K��R)bׅ�ʈ��3�@䖷縝�Q��ne�=�noX ��Bk1.�L|�y�6��Q1�ӿTV��� H�Ŝ����I��Pi����l����}��p^�28/�ԛ،�d:4�#a����{�qb�žD��T�\[�!>�^�?8����z�Mי�dKX*p�~(TS�3��ib�������������Vl�=6oN���wyƜ*>���[�7���;�4��<-����������)T�|�7a®h�ʘ �c1 �/BΎ�K��/ J�WCu3��Y�������}�қE�y��C:��"`�<����@ u���PPAQ���[kj�5in}���{���;K�o�3²A@�L*"eAdgzMc Qñ"��,��^�ykH���`8���&R�g]ñ���4┿r��BS׃A�
b�F�'΍���-�0&�}k�͊SX���D���2�[p���@}+p���^�at��

�ǯ�=�Z�%ő�9����M¬Q���&q_2���?9� �#,��>�k&�5�Y���xEn�Q��Q��:R'���HݎJ����o� ��y��F�9w>��I]�͂�-��ndU�q�9�[�A��|�����-PH�&�>�aTj�j54`�!®� ��̻�5ڎ�*�
�oЅ�(�&ך�...���N�5z�n�|�:�W����_���T���B�t�]���i�B���:���-�O7G�{zS�@����J["����Z��U��vQ'��/�~�{d�<�x����qLoQ�%O5���,�Y;s�Po'H��U��Ezz7S�d9�-{Ɛ�V�&��Z�����C�j]]��Ң=렧����W{�����b�����#��s�F��,�4�~��B�����=�<�d;(�˘3��c�(EE���A��c�2�1->

stream

x��Z�n�6}����j�KR���M�4A�:���{/�DZS�__R�+�P��c�6`��N�{��/K΄\r��

ۛ�χ������<� łu¾lxs�8jł��̩A;��K���@۴P�#b|��I���LnQ�^�~��n �ɳ�D����z)����RWP��/&���cC2^

-NbuP
�M���ή#%���^[�:w���Ќ�Ds.��3v��Xa�ŷE^

֔p����v���O�)sͅr�����J��\ݏ�/�.�J����z������+;�.%������@�%I��t�*�����Z�=+6>@��F��d�]9�-��j�:�2�a��$� Y��-a�f� ��|t%�5�ʈ����a��$g���3�1�

��s;�2j��?qg`F

�B�آ ���Ȧ `00��Z�ai��C[�mk%'y'��|Z.���%�Ji�i�UWBB��-,3<��`� X�Ϲ;P+��#dSz�!:A9�㞟 �2��ub��=�TN�e; �";�h��[=

����y"�93�i��� �7�`�h��wTS�k�W�[�*"QkO%�9]��Xh��R�>͔�=�>�Sbׇ4j�sϼ��@4��mN�O~��N�R���~���O�bJ,��F
Փ��5��!���=ECB����=D�@xeo

&d��`�vs�0�F�M��|�h���FX`�)�tv�Gr�����s����M�\k� �:&q�G���z��C�h����
�L�����ì�Q��/���z y��>M�S$a���o좬5���~�o.�Q��3����+�n�o,:��!b8\_�B�!6wb�_W�{�F�\4�G&�����K��* �)�"���WB_x�1�}G�M���!U̶��X��R2z�Q- �d=��ѳ�iRRqa�R�sR���3�Lื������GE�c-Ы���

�U�.SL�4E�z/�8��Ue�}��We��֓�����c�@��;�Ɋ�[_|�wMPǿ=�7�i���$��ڛJ��W� ���7�t:WE+�g��C���m�˲�Vpk�����k�=�=@nzB�fF,i�Ea����j�WX�޶,[j��

_4c�"�����u�ahWUS`��Me����9�权�Mm���a?��G��45>�1b�
�¶
3����P��A�IS���N�i�j������]T@endstream

endobj

18 0 obj

2031

endobj

22 0 obj

<>

stream

x��Z[w�6~�_�o�{j����'�) �[�RNON �&%W����/�٣�7��hmi��|�i䫥J/e�Gg�;�r�q�>^<�֋�E%L��>�����Tj����r�n!E]W�n��cY-K鄭����a�(��R����n^(�*glv//���H�-s%�tJg�%t��S��2/4e�=��ϛ�u��d�����]v�V�ZC� t�B;���^�f� ���kP[:4O; t-�l//<���jVP Ъj���z�0^H_��B���0oY���n�e�XN� �j�/��Ę���Z�u8�z^7ڕ�4��>E��[V:�c^�|����A�+��,W�P�2T.��K���t�?h"23lB ���>����MI���"��'��&

]�j���&um`?��6LjC�]��Y�G��R�

ͩ��l���1Z�v��0p�&�-V?��7|<���#|OV��C��7� i���Q��B�6�]Y�������� B항��kᕃ�I�A۵���Y�$� �6����'��P�tE������'ፒVT�&�^t���ٳn�w����Cnz�§Bh!��v�+%�',6�J]S���tcDG"(F�RN��R4�#��(,٥�PI�`�!1؁.��k�2�<:b\kO���[��nPk >���[��ܪ.#��1��1N�V'V�����:a����.)���|,:E,�y�[�M��Qb#gx�&��-�i�Q��8�nL�����I�T�i�&�qQ�2�e����h���Zן����gRG� k}�gh,<�O;_�� �Z��`|�� ����� �����K,��[�řM�N�fF�~���a㤱�f�6�cv~����h��cs�<����v�*:� $���c�[V��8{R�M� �{�4��
>�$�(�

hb!�V����J��1��H�i�o`���YyD�F���K�j�i��s��+C�̢
~�A�l#ßa��sרk��8�)����� ��z�8U�5�V:�a�IUp���:��..�H:�I��lv�a��0]��u�'$���y[
>�[sP����\� Q3���!�H���/�c]��Mhxn����D��â[����Jˎ��;K��ŢU�xx�!������V٨�ipx��v

�N��B�)�����.�(��*`FR!�=q���c�@�mc�����֚VZ�+�u��b���l�6܄0��H����F�7c��H>���wNs������۟H��/�`{?
d��#*;(���ʖ�?'���*�F~~��K�����y���oz���zu ��p�sd��P�k֞7���� 9]�^9u;4M6#��8�۬��lN��U�mF4�'� �T2��u�A/1�#�N�T%|�)�]���w�(�[u|כ�
���.`R:� kK3*���t}�1<�����#�O�DN@{q�*v���z��)���Reʊ�A���(}��.��1G~,
�:p�"@�\���O�,�PT?-�$�Z}c�~����W[i��s�67��aQ�O^�n�J�-?�g?�s�N�#�V�e'x7v�/+�AXט�3ǥ���H�M��>N&��%ܖ��%�=�~�u__���3��Wx�K�;5�V^X�}�Pj�to�����X�endstream

endobj

23 0 obj

1758

endobj

4 0 obj

<>

/Contents 5 0 R

>>

endobj

16 0 obj

<>

/Contents 17 0 R

>>

endobj

21 0 obj

<>

/Contents 22 0 R

>>

endobj

3 0 obj

<< /Type /Pages /Kids [

4 0 R

16 0 R

21 0 R

] /Count 3

/Rotate 0>>

endobj

1 0 obj

<>

endobj

7 0 obj

<>endobj

14 0 obj

<>

endobj

15 0 obj

<>

endobj

19 0 obj

<>

endobj

20 0 obj

<>

endobj

24 0 obj

<>

endobj

25 0 obj

<>

endobj

26 0 obj

<>stream

x��X T�g��cL��֥��$j�jպT�V�Z7�** ���v;I�J�$�,@�d�eE�nck��]�V�0���3s��gf��{ν��p�|��>��>�� &O"�Tߨ8Q�q\X�����l=g�&s+������M³�9 Le�����)u��fҌ��k����Ó-�iRTDd�ۂ�>�-Z���,_�f��a�߿q�%GEĻ��IŊ�D�)kݶ�ѱ�QG�"b� ��naG���:���ŊbܶE�F%$���lY�bٲ�K��k���Ɖ�ċݢ�ã�R�na�G��Ɖ"���Ž��x�E�$I�V.�����=Qq�S��Ư�G�����G�������s�4����2���=[DA{=ý�&ExoK��ٞ�oGj��δ����dž����7.X�x��e�W�V�|�� �oA�^ƒXJ�C^�V�#�}b.�Ml#�ˈy���XN�K�#v+���/����X@�'>!V ?b��x��'<��ED���L�&��b�NP�+��AL#�3����!��7�tb61�؂NL��8�X�h�Ě���1�� ��N��H��M�C�M�<���E�P/^���`J���^=9u�ԫ�|�=��nzጥ3��6�5�k�gN�6�v�t��xp4�����Kq�ol~���5ȵ����0�5�ϝg� �W��g�>K6�c�ߠa: �Cr�����ӈ+'��n��D��,��P;؛���B:�7m��E��K�;z�l�ƼHN'ت�o΢$$���>7�����ߪd��9� s�T@_祳��1�.��*#8�/�A28��`1؊��
�

��=�, �D���$��/��@9��f.$a�Pk:���G�Sv-���h���R������� �C����z[���A���W@��aY�]�6� ��Z{\C`Y��<�S�HL�(�dh�$FY�P)����-I�����¥�bkK������;=�<��0�f��os� ��R@5�ȃ�(�>jE@6%��v2�Pn
l#O����j�6v��H੔:��AE*���|zaSH�l�v�CRW$�R�f��4�hV#��}&�6\� ����e�A�O�o>����T��BZ�uՎ�[O�

H�8,o�(��å�y����CP_�o�DM��4���`@F?]1�����;Hw�rN*lu���6p���0��;��$J+@t
I�O��*��{�sw=��r��j�/=���c'Y6����1�:ao7�tJ.�5�F>��+��|�=��β��&'��&��=lj*�7�p�������8��ݱ�q� �O��Z�̵U��X���g��bm�A�p_���9�]L�?�9�O;z$%FzX�PA��!왌�����Xb��!y%x�z��%Bj�D�jb���\i�&P�������@!
V�Yv�3����*�%���ˀ�6r�-d��i$Ƈ��^��h�ھeB}���X� ���߅.���oP]��
�.T��×�7����G�k�ӄ�_��p��M�s����F�3�>̄/5\8�,�����@EhK��Ȭ�`Y�f���A�� P�%��B���$��''�"z�~w%�t���d�p ��N�Ҩ��I�x@��>�3 k�νO� �+y706��!��}6�\��&K�)G�4Z��e���z���3(��@i���rm���[����f��h�ec�\r�+

p��~$\Ӯ|]W}����TWi���8A�A�+�M��t .�;V��V�U�WIȮ[�=�RQ
vS�[r�KKXh���l����n�#�=P�!�{0,1(��{\�����%0�d�4V[���J�@n����5�=v���ݢ�MK�V����E?
�? \yLI+6y�s|O���P��`�2)��{�

�w�lڑnAK�]���r�X\��z���/�����\9��MnI���ͨ9 �$9��_���S2�#�Y���Rp������ZM/ߔ?��p|m�7��M�*�O���E*}e|��FnӅ��;���A���h8)�����s�7��|������.]k�

^ak�k�Z�:B��A 8 E8��
��J��

�?ܽ�^
zsK�u^
W@�غ�r��.��.}zpe�4i��I�

LZ�̦=��X��2m`ձKM��U5�'l���$��v���+�

Y=��D�A�{� ��!� �6��E��4�,iYv�[8���ѯ��@8������^z~��c���`@�s.�y @�/�t��$YRJJd�A�
+"�����# /{OR����j�$��S'_�y�fC�+��ϐ�[T� �m/v�!~m�z����o�K�m���ۿ@��&�8�F�~�+���6����6��z�]ψ:%x��g@@S���@@��j%���0?M��\�]�+]j���aW�c8F��r^ևĕ��f.B�q\>[�|�|ݩ~!�̹O*�ȢdPm#}-Z�8����f�$g+5�TI�*ĂszeLc�u��y �|z��������no�[�|s��`g@�=�hi�+e�M9�j5�u{w�%�$

C�yk�51O��l�Y����lV;�Ơ.w)�9����S����ig<��x��a?�.�<�<��}��[:���@��+��H�ʆ%8��Q��}Gkր-��V��j6�&:�:��nSt�d��ξz`�{^��LW��&dN'��[ WuI&�N���ف�8���
T;��Y��RPNA��O�]iu�j�<��;�-W+�2���R�������p6@��|9u���ˁ���a������dt'{<������Fz�f(ɷ�XIF�H���R�����v��.R0�l�;]_\��)�)J�V@���Z�*���S<��� �/5B�%Ꮻ����1}��������������DG�<���t�i��T/��P����nڲ̳^�Y�P"���Y���t��,��t��<���g�=��޳��������d@�b�_AR (��������n�vC�83�W�.lZsi��xXK��䓾���C�`�d��U1};:�����s�-�b���O�� �<���d���^4��3���j��8���7t�J'�.� �Z+��ŀ��
�P�˜�

���.���qnqb��B��nQ0�#�r��#�_S�QE/�TV���

�|�9 ހ�s9���l!rs3uyyـ��u� Sjja��u>
[��y,�nO/O���q@T��Z"H;�Y��He�9�h��4�,82��=^@�P�]1����<�ܺ�C��?����@=���a�bSԊ��.�}�q{��ܱ���4���c[�(��5Jo��0�o֛�& ;��WX��
�Hf�TI�}�-+�,�7�"@�����c1�����Zegb#Ź�#r�[2�s5J�w�f5F��)�p싔Vg��0]a�U�`��s���� gZ�!�$F��:ۅ�^���*�^7�#��%s4���LRv_�%Ǣ�g��C���ٓ����p������W�o�`Pr<�I\�plU���V*[/�*Ҁd�ƃ��A��X}�G��o��%�|���
8������$�d�Q�a3V�S[_┘0����ܜg�t��L�F�{(8#[���@���5�R��s��M�. v՞m(KӒd�T���_�㿐xI��k#��[���}_�OK�5��kǩLN�-�6g��ɝEZ�3���i܄���:������!�&��O�Ui���*�����3��ŕ3H�í>����V���/3���M1��E�G�JÀ?XۿN��%:{���DY��)�|G`������@A

�3؄"Y��|��f�ݳ�.y��k�z�{�n

�

���]WO�J"��1��2/\��v�v:�F�PKWp������f y_W��{{Ҩ�;K��An,�0�I������o���_WA~�Fb��+l.7��a�N>��b����/H�}�Bƾ�cр@

�H �R(� ���8@�i�rN���]y*�&!*"ם

��y���^���r'sOWv����qR�#� ��C�Y���K�EQ����o��.�$ؐ��N�kZ��QV%�Q�d`�,���t����.݃oF7�^�q;��e@#�q�����C����rM�����s$d�ji �Dղ��c���}̪e�BF�N�܋��E!�b�S�mT�Vc�O������:�t �%�� ���Ko�3�D����-9v �M�&[�Yx�`�ޖc%�Ք� ��ɮ\�f`.���yz�Π-�k�A10Z��ux��x���d�&�p�����Q&W!�jV��H�������v2=�H
�0�|�IB7�א]�S�c��4=Ȣ23�*�D���PC�#�Z�x��7?�:�h��mX���萂}<�4(�6S�PaW9�G���"U��;������������~& i�Xʞ�qp��,̧�[�u�����]���M8)m�u:���q�>r�CB>�c�n��umz�~w�o������n���'�'��>��KK;��%䓉�cGȃ��D��tL'дg�aQ�����7�+��L��� �-9٦3������(����V>�.5�4�\����l��r�Qb�K��`�h�6皁��,��B�ݦ�^��귷�m<�
��@�Љ����C�?_a^�)��}�׍�e�E|��e�ng��7`����b���0����o*k����

9ٔk���R�R�b��*�2]Q��JۀجƦ|�#�� �)���rp��EdS_k��.V$�Q |�Zo$���q�

p��p���{$z�H/F���@�p���I��W�4���k�/�a��L�dt=7� L��=���;�[q~!0��$3L8VF�>�~y#p|���|�t����';�>8�MG��]k��L�������_��}&�/
��5b4���x�ynQfu���Y�w�^[c>�_����g�l[ۺ����\z��"{�y��ff�b�6Z�?\�'�zƄ��t���2r>@���\�����Գ1�2��k����ɟ����'�W�6u�r���1��V�SMu�7��}�t���_~0r�Tb��*��ȳ>�ac�� `>xG鞰G���/`����[��SLj�'N ��1�C3��]��f�3��%%��Kjl�;�؜X�|�Pԍ��1j_@�g�v���0Yx��>"���hE����z&y�
}��C� �4

�-�o!WAN"w�b!���Z�xF���g��d�(�~�Cώe,i)*-,,�0��ZU"�:_���)��LEN��"���38E�/���]s�
�{Ƥ��M��(�G�y� �A�o�?~<�����w|�S��b��12��,^��-_j�����!KW��mț��g�U����{(d����vD��R
����5m-)�=6^XY��(������q�S����Ne��!�~Ʉ;�G\�.�c�7�L�>stream

x�cd`ab`dd��H�)K-�LN�H3��a�!�,��3�o7s7ˢ�B�K���``fd���_PY���Q�������1���TH���(��g��)�
e�9���y%�

�@�99��

�9��

�))�) ma�9��

n�9��e

Κ

F��@��/37��X!81�X�G!(5�4'�E����Q
��Yؿ����E?���;�g�M�{�7'��<������R�

endstream

endobj

29 0 obj

237

endobj

30 0 obj

<>stream

x�eU{PSW�!��kAls'��d\E�U�J�.ZA�-�Z|�E �^!$���3��Cx}�** �Gi����V�

vwܝjGם�î��w3�?�\t��ӹ3g��9��w���������$��.]�6oe�Q���%�a�Y�Ȼ]���;%�����߷{
;%�+o@�<({��J$��h��ج���W��N��|���߬���P��/�ު��e�!�P�7�r���w��d�^�KWg�MYy�T�F���I�ks��tz��d,T�F���Z�z�J�����M+�S'sS �c�:N���

r�(J�%*)!�í;b�۹}������ZD���H�I-�VSK�5T��

��Qa�zjNI(����Rw%I�;>�|z�>R�t�� �d��2���f�1-L;�x�D���K��Ax g�ʡHa��#��Y9i;�7!6���=�&[\��X���ܩ:U���3�D�JQGY3Ù�I:��A �A�%a�[� zcxE�A%�I�����46όhW�8̙̐B@xfG]~:�\�|痭�����l�D,gB��eY5,7X�J��ɍ�� ���L58���*��o酱p悙���u�"�� �ڼf�nUǫ��>ۑ�cb�0IC$�N�l�2�գʺ�k�ie�B`�=C~�|�W�e~��@s���wc�eiIS���*�/W�I���x���x^�r�^��@�K�fl2ӷ+ۏ!�س�iX�ヰ?؎�V6 l竚P��Z?��O�x����9cq� ���2(�� ��4�Dԗ5� �� c��M�'� kqg��+1,Dr#`�3ʹ�ۮ&�3���D�]��̦���+�0܈�sfHvNxD��\�?4�6瘙��B���_3�r�;�/�-�1��]�X������b8�]aD
è��=4�B����O�֣�h��6�+�}����澿��`*��p�2�(�|+b_�:|����?;!d�=���� 3��pp����2;V���e�Ȍ�~{�1Ӑ���d3bcES�J$hHӌY�<=L�0���� l�EW�(�}M��y%��`����@����́�Co

�(F��2N��A7;x�9��ٶ�h�妀 ��c��C�

�-6-V
E��E�"~�3��eMDİ�,��[��3�”9�Zk����v�����C�bm��B�a��|�����$��Ձܔ�

.+�Of�Qe��f1���R;<�ʔ������R�����ң�ֽ���_�{���F��C�s���8��A���'���K��� z,n�0H��Hy�`T@n.S~��1+�u��ض�s���x��MX�v4�U�s~L=}� ޶�এ��kZ�i��gg ���|}C�GM�]�׭���B�� �L���U��7^.�����z��ȧ��O��Ym�b�Hﾼ=��ߤq��'�I���o��>

�x&��ą��q���;'��<33�����t\
鳑q1���ܮ8e#э��Jc�~>ᙨzkA
+3+YaO'�sK�IH�2G��8���^/Ϭs:�V8������v�Ǟ�k Y63EW�d�y��F?���H��_��LD���@I��wE��<�����Φ>��6QK|nf�Uv��D��w�+�%��09,�J�[

t��mL�I�/�c��E�6�Cwn�~KބJx̠�ή֖�ƶ���%[��j�7� c���M�լ���h�wyG.�y���
�\�Rݰ�M��j��>Pw�ϥ��-�?�

endstream

endobj

31 0 obj

2045

endobj

11 0 obj

<>

endobj

13 0 obj

<>

endobj

9 0 obj

<>

endobj

10 0 obj

<>

endobj

12 0 obj

<>

endobj

8 0 obj

<>

endobj

2 0 obj

<>endobj

xref

0 32

0000000000 65535 f

0000007181 00000 n

0000018554 00000 n

0000007099 00000 n

0000006615 00000 n

0000000015 00000 n

0000002620 00000 n

0000007229 00000 n

0000018303 00000 n

0000017323 00000 n

0000017628 00000 n

0000016642 00000 n

0000018066 00000 n

0000017165 00000 n

0000007270 00000 n

0000007300 00000 n

0000006775 00000 n

0000002640 00000 n

0000004743 00000 n

0000007352 00000 n

0000007382 00000 n

0000006937 00000 n

0000004764 00000 n

0000006594 00000 n

0000007425 00000 n

0000007455 00000 n

0000007507 00000 n

0000014126 00000 n

0000014147 00000 n

0000014470 00000 n

0000014490 00000 n

0000016621 00000 n

trailer

<< /Size 32 /Root 1 0 R /Info 2 0 R

/ID [(��w�u�}�)(��w�u�}�)]

>>

startxref

18768

%%EOF

Prevalence and Characteristics of STRC Gene Mutations (DFNB16): A Systematic Review and Meta-Analysis - PMC

Prevalence and Characteristics of STRC Gene Mutations (DFNB16): A Systematic Review and Meta-Analysis - PMC

Back to Top

Skip to main content

An official website of the United States government

Here's how you know

The .gov means it’s official.

Federal government websites often end in .gov or .mil. Before

sharing sensitive information, make sure you’re on a federal

government site.

The site is secure.

The https:// ensures that you are connecting to the

official website and that any information you provide is encrypted

and transmitted securely.

Log in

Show account info

Close

Account

Logged in as:

username

Dashboard

Publications

Account settings

Log out

Access keys

NCBI Homepage

MyNCBI Homepage

Main Content

Main Navigation

Search PMC Full-Text Archive

Search in PMC

Advanced Search

User Guide

Journal List

Front Genet

PMC8491653

Other Formats

PDF (3.4M)

Actions

Cite

Collections

Add to Collections

Create a new collection

Add to an existing collection

Name your collection:

Name must be less than characters

Choose a collection:

Unable to load your collection due to an error

Please try again

Add

Cancel

Share

 

 

 

Permalink

Copy

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

Journal List

Front Genet

PMC8491653

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,

the contents by NLM or the National Institutes of Health.

Learn more:

PMC Disclaimer

|

PMC Copyright Notice

Front Genet. 2021; 12: 707845. Published online 2021 Sep 21. doi: 10.3389/fgene.2021.707845PMCID: PMC8491653PMID: 34621290Prevalence and Characteristics of STRC Gene Mutations (DFNB16): A Systematic Review and Meta-AnalysisShuang Han, Dejun Zhang, Yingyuan Guo, Zeming Fu, and Guofang Guan

*

Author information Article notes Copyright and License information PMC DisclaimerDepartment of Otolaryngology Head and Neck Surgery, The Second Hospital of Jilin University, Changchun, ChinaEdited by: Rahul Mittal, University of Miami, United StatesReviewed by: Ruixue Hou, Icahn School of Medicine at Mount Sinai, United States; Paul B. Higgins, Letterkenny Institute of Technology, Ireland*Correspondence: Guofang Guan nc.ude.ulj@fgnaugThis article was submitted to Applied Genetic Epidemiology, a section of the journal Frontiers in GeneticsReceived 2021 May 10; Accepted 2021 Aug 13.Copyright © 2021 Han, Zhang, Guo, Fu and Guan.This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Associated DataSupplementary MaterialsData_Sheet_1.docx (1.0M)GUID: 065192E1-825B-4E11-83E5-950467CA7A47Table_1.docx (33K)GUID: 37D3B17A-D865-4269-B53F-678D9945C85BTable_2.doc (92K)GUID: F9E1F3F6-1E03-4588-9F2D-C0D5716C69B9Table_3.doc (92K)GUID: B2933365-CBD9-4460-8685-98ECC4687928Data Availability StatementThe original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.AbstractBackground: Mutations in the STRC (MIM 606440) gene, inducing DFNB16, are considered a major cause of mild–moderate autosomal recessive non-syndromic hearing loss (ARNSHL). We conducted a systematic review and meta-analysis to determine the global prevalence and characteristics of STRC variations, important information required for genetic counseling.Methods: PubMed, Google Scholar, Medline, Embase, and Web of Science were searched for relevant articles published before January 2021.Results: The pooled prevalence of DFNB16 in GJB2-negative patients with hearing loss was 4.08% (95% CI: 0.0289–0.0573), and the proportion of STRC variants in the mild–moderate hearing loss group was 14.36%. Monoallelic mutations of STRC were 4.84% (95% CI: 0.0343–0.0680) in patients with deafness (non-GJB2) and 1.36% (95% CI: 0.0025–0.0696) in people with normal hearing. The DFNB16 prevalence in genetically confirmed patients (non-GJB2) was 11.10% (95% CI: 0.0716–0.1682). Overall pooled prevalence of deafness–infertility syndrome (DIS) was 36.75% (95% CI: 0.2122–0.5563) in DFNB16. The prevalence of biallelic deletions in STRC gene mutations was 70.85% (95% CI: 0.5824–0.8213).Conclusion: Variants in the STRC gene significantly contribute to mild–moderate hearing impairment. Moreover, biallelic deletions are a main feature of STRC mutations. Copy number variations associated with infertility should be seriously considered when investigating DFNB16.Keywords: STRC gene, mutation, deafness, prevalence, meta-analysisIntroductionAccording to the World Health Organization, one in five people worldwide lives with hearing loss (HL)−5.5% of the population of the world (World Health Organization, 2021). Hearing problems can have a devastating impact on the mental health of the people and the ability to communicate, study, and even earn a living. Approximately half the cases of deafness have a genetic etiology (Sheffield and Smith, 2019). Although variations in gap junction protein beta 2 (GJB2) gene are the most common factor for prelingual, recessive deafness (50%), stereocilin (STRC) gene, known as DFNB16, is supposed to be another major contributor to bilateral mild-to-moderate hearing impairment (HI) (Francey et al., 2012; Yokota et al., 2019). Moreover, STRC mutations are considered the second most frequent cause associated with autosomal recessive non-syndromic hearing loss (ARNSHL) (Sloan-Heggen et al., 2016; Plevova et al., 2017; Back et al., 2019; Cada et al., 2019).The STRC gene is located on chromosome 15q15.3 and named after its encoded protein—stereocilin—an extracellular structural protein expressed in the outer hair cells (OHCs) of the inner ear. Stereocilin was detected in six sensory areas in the inner ears of mice: the organ of Corti, the utricular maculae, the saccular maculae, and the three cristae ampullares of the vestibule (Verpy et al., 2001). Stereocilin was associated with OHCs in two cell-surface specializations interconnecting with the hair bundle in Corti contained with inner hair cells, OHCs, supporting cells, ciliated ends of the hair cells, and the tectorial membrane. The two specializations are the horizontal top connectors of adjacent stereocilia, which have a zipper-like structure, and the attachment links that anchor the tallest stereocilia into the overlying tectorial membrane (Verpy et al., 2008, 2011). In stereocilin null (Strc _/_) mice, both these links were absent, and progressive HL appeared from P15 (Verpy et al., 2008, 2011).STRC has a tandem structure, and the linkage region includes three other genes: CATSPER2 (MIM 607249), PPIP5K1 (MIM 610979), and CKMT1B (MIM 123290) (Zhang et al., 2007). Causative alterations in the STRC gene include copy number variations (CNVs), single nucleotide variants (SNVs), or small insertions/deletions (indels). Recently, CNVs have been recognized as having an important role in STRC variations (Yokota et al., 2019). The STRC deletions are frequently accompanied by the deletion of the CATSPER2 gene accounting for sperm motility. This genotype, characterized by deletions including both CATSPER2 and STRC, is known as deafness–infertility syndrome (DIS) in both males and females (Hildebrand et al., 2009). STRC is part of a tandem duplication, and the second copy is a pseudogene (pSTRC). The highly homologous (>99%) distal pseudogene makes molecular analysis to detect STRC mutations by next-generation (NGS) and exome sequencing (ES) challenging (Vona et al., 2015; Shi et al., 2019). Reliable screening is especially significant and affordable in recent years due to the development of analytical approaches, such as MPLA, long-range/nested PCR, and droplet digital PCR (Back et al., 2019; Shi et al., 2019).Many studies have routinely described genetic testing of patients with DFNB16. Compared with other deafness-associated gene variants, STRC has its own unique qualities and may lead to non-syndromic or syndromic deafness. However, to date, there is no publication systematically describing the prevalence and features of DFNB. Against this background, this meta-analysis provides a global and current pooled prevalence of STRC mutations based on available gene detection. Results generated from this paper will widen available options and contribute to genetic counseling for medical workers and individuals affected by HI.MethodsThis search was performed following the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Moher et al., 2009) (Supplementary Table 1).Search StrategyThe literature search was conducted by electronic databases (PubMed, Google Scholar, Medline, Embase, and Web of Science) for the English language articles published prior to January 2021. We entered search terms (“STRC” OR “stereocilin” OR “DFNB16”) into each database. Two authors (SH and DZ) separately undertook literature searches and checked the reference lists of all selected articles. When disagreements occurred after the screening, further discussion took place to reach a consensus.Eligibility CriteriaWe included researches that met the following criteria: (1) original research, (2) study population with HI and sample sizes with no <10 probands, (3) STRC gene detection, and (4) available full-text papers written in English. We excluded (1) duplicate publications, reviews, studies with overlapping data, mechanisms and/or animals, abstract-only articles, and texts without raw data; (2) fewer than 10 probands reported; and (3) studies published in languages other than English.Study Selection and Data ExtractionTwo authors (SH and DZ) independently accomplished the literature selection based on predetermined criteria. The other researchers (YG and ZF) reviewed whether the results were consistent. If disagreements occurred, further discussion took place until a consensus was reached. A standard data extraction diagram is presented in Figure 1.Open in a separate windowFigure 1Standard data extraction diagram.After relevant publications were selected, the data were collected by two reviewers (SH and DZ) from included papers as follows: first author, year of publication, region, study population, gene detection method, DFNB16, genetically confirmed cases (non-GJB2), total HI patients (non-GJB2), DIS, carriers in total HI patients (non-GJB2), carriers in the normal-hearing population, and types of mutations in STRC (biallelic CNVs, CNVs + SNVs, or small indels, biallelic SNVs, or small indels). Discrepancies were discussed and resolved by the senior author (GG).Quality AssessmentThe risk of bias in each observational study was calculated using a tool developed by Hoy et al. (2012), with total scores ranging from 0 to 10. Bias was judged to be of low risk (9–10 points), moderate risk (6–8 points), or high risk (<6 points).Statistical AnalysisThe meta-analysis was conducted using R (version 4.0.4, The R Foundation, Vienna, Austria). To bring the proportion data closer to a normal distribution, the logit transformation was used to solve the estimates < 0.2 or >0.8, while the double-arcsine method was chosen when extreme proportions (0 or 1) exist (Lipsey and Wilson, 2000). The Shapiro–Wilk normality test was applied to calculate the normal distribution of the transformed sample data. Assessments and 95% confidence intervals (CIs) of the prevalence of all collected articles were estimated by the random-effects model. Forest plots were used to show percentages of each study, the summary rate, and heterogeneity among publications. Between-study heterogeneity was evaluated by the I2 statistic. Meta-regression was calculated to investigate the potential source of high heterogeneity. The sensitivity analysis was completed by removing low-quality papers (score ≤ 5) and determining whether the results were stable. Funnel plots and Egger's bias test were used to assess the publication bias.ResultsA total of 294 publications were extracted from the databases. After duplicates were excluded, titles and abstracts of the remaining articles were screened, and full-text versions of 73 relevant studies were further reviewed. Finally, 37 papers were included in the meta-analysis and were used in the subsets shown in Figure 1. All detailed information extracted from eligible articles is presented in Table 1, Supplementary Table 2. The prevalence of DFNB16 in HI patients (non-GJB2) was 4.08% (95% CI: 0.0289–0.0573), the prevalence of STRC carriers in the HI participants (non-GJB2) was 4.84% (95% CI: 0.0343–0.0680), and those with normal hearing accounted for 1.36% (95% CI: 0.0025–0.0696). The prevalence of DFNB16 in genetically confirmed cases (non-GJB2) was 11.10% (95% CI: 0.0716–0.1682), the prevalence of DIS in DFNB16 patients was 36.75% (95% CI: 0.2122–0.5563), and the prevalence of biallelic deletions in DFNB16 patients was 70.85% (95% CI: 0.5824–0.8213).Table 1Proportions extracted for meta-analysis.

References

Region

Study population

Gene detection method#

Frequency of DFNB16*

Carrier-frequency in non-GJB2 HI

Carrier-frequency in people with normal hearing

Frequency of DFNB16 in confirmed cases**

Frequency of DIS in DFNB16

Types of mutations in STRC

CNVs

CNVs+ NVs or indels

SNVs or indels

Sheppard et al. (2018)USAHLNGS+CNV2.50%2.50%7.14%Lebeko et al. (2016)CameroonARNSHLNGS+CNV10.00%Marková et al. (2018)CzechNSHLNGS+CNV5.56%4.51%37.50%50.00%43.756.25Plevova et al. (2017)CzechHLNGS+CNV10.20%35.71%Chang and Choi (2014)KoreaHLNGS0.88%1.56%Safka Brozkova et al. (2020)CzechNSHLNGS+CNV5.23%2.61%40.74%50.00%36.36%13.64%Kim et al. (2020)KoreaHLNGS+CNV36.71%60.42%44.83%58.62%34.48%6.90%Schrauwen et al. (2013)EuropeARNSHLNGS8.33%Kannan-Sundhari et al. (2020)IranHLNGS4.35%Ito et al. (2019)JapanNSHLNGS+CNV5.95%2.38%0.93%Back et al. (2019)GermanyARNSHLNGS+CNV10.98%Mehta et al. (2016)USANSHLNGS+CNV2.41%37.14%Morgan et al. (2020)ItalyNSHLNGS+CNV7.53%21.21%García-García et al. (2020)SpainHLNGS+CNV2.75%0.92%7.89%Morgan et al. (2018)ItalyNSHLNGS+CNV1.94%6.25%Francey et al. (2012)USANSHLNGS+CNV2.58%0.52%52.94%29.41%17.65%Gu et al. (2015)ChinaNSHLNGS+CNV1.59%Yokota et al. (2019)JapanNSHLNGS+CNV1.95%5.28%2.63%7.05%88.24%100%Downie et al. (2020)AustraliaHLNGS+CNV4.76%10.81%Sommen et al. (2016)Western-EuropeanARNSHLNGS+CNV0.76%8.40%3.45%Zazo Seco et al. (2017)NetherlandsHLNGS+CNV2.09%6.90%Vona et al. (2015)GermanyNSHLNGS+CNV6.38%5.32%Shearer et al. (2014)USAHLNGS+CNV10.81%83.78%16.22%Budde et al. (2020)EgyptNSHLNGS+CNV1.75%2.27%Cabanillas et al. (2018)SpainHLNGS+CNV4.00%8.00%9.52%Moteki et al. (2016)JapanNSHLNGS+CNV1.55%5.77%Sloan-Heggen et al. (2016)USAHLNGS+CNV6.93%20.58%23.94%77.46%21.13%1.41%Mandelker et al. (2014)NAHLNGS+CNV63.64%36.36%Bademci et al. (2016)MultipleARNSHLNGS+CNV0.63%1.11%Baux et al. (2017)FranceNSHLNGS+CNV5.70%18.00%Ji et al. (2014)ChinaHLNGS+CNV11.27%Costales et al. (2020)SpainHLNGS4.55%10.00%Sloan-Heggen et al. (2015)IranHLNGS+CNV0.33%0.50%Guan et al. (2018)USANSHLNGS+CNV8.00%18.18%Amr et al. (2018)NAHLNGS+CNV35.48%74.19%22.58%3.23%Shearer et al. (2013)USANSHLNGS+CNV4.26%1.06%11.11%Brownstein et al. (2020)IsraelHLNGS2.27%3.77%Open in a separate window#

NGS including: panel, targeted testing, ES, exome sequencing; CES, clinical exome sequencing; WES, whole exome sequencing; TGE, targeted genome enrichment; Sanger also included; CNV including: MLPA, QF-PCR, long-range/nested PCR, microdroplet PCR, droplet digital PCR, array CGH, SNP microarray, CMA, chromosomal microarray analysis; QCF PCR, quantitative comparative fluorescent PCR; MPS, massively parallel sequencing.

*

The frequency of STRC is achieved from GJB2-negative patients.

**

Genetically confirmed cases except for GJB2-related.

Quality AssessmentThe details of quality assessment scores for each article are available in Supplementary Table 3. None of the included studies received low risk for items 2, 3, and 9, as the cluster sampling method, random selection, census, or the length of the shortest prevalence period were not provided in each survey. Out of the remaining 7 possible points, 4 studies received 7 points, 13 studies obtained 6 points, and 20 studies received 5 points.The Global Prevalence of DFNB16 in GJB2-Negative Hearing Impaired PatientsThe proportion of STRC mutations in GJB2-irrelevant HI patients varied from 0.33 to 36.71% among 33 studies (Table 1), with the highest rate observed in Korea (Kim et al., 2020). The overall pooled prevalence was 4.08% (95% CI: 0.0289–0.0573, I2 = 83%, p < 0.01) using a random-effects model among 6,325 subjects (Figure 2). The I2 and p-value indicated substantial heterogeneity.Open in a separate windowFigure 2The global prevalence of DFNB16 in GJB2-negative hearing impaired (HI) patients.Meta-regression was used to estimate the source of heterogeneity. We investigated five categorical moderators: region (Europe, Asia, America, or others), study population (HL, NSHL, or ARNSHL), gene detection method (NGS or NGS+CNV), degree of HI (mild–moderate or other HI), and quality assessment grade (score ≤ 5 or score >5). Significant estimates were not found for moderators in region, study population, gene detection method, and quality assessment (p = 0.9351, 0.8068, 0.6876, 0.8419). The degree of HI was significantly associated with the overall pooled prevalence (p = 0.0003). The R2 (amount of heterogeneity accounted for) was 49.91%, meaning that the degree of HI can explain about 49.91% of heterogeneity in the DFNB16 prevalence among GJB2-negative HI patients.The prevalence of STRC mutations in GJB2-negative HI patients was further analyzed by subgroup focusing on world region (Supplementary Figure 1A) and the degree of HI (Supplementary Figure 1B). For region, the highest rate estimated was in Europe, which was 5.40% (95% CI: 0.0409–0.0711), followed by the US at 3.94% (95% CI: 0.0222–0.0690), other regions with 3.00% (95% CI: 0.0103–0.0841), and Asia at 2.77% (95% CI: 0.0075–0.0965). The estimated prevalence of mild–moderate HI was 14.36% (95% CI: 0.0365–0.4259), and that of other HI was 3.67% (95% CI: 0.0281–0.0478).To estimate the stability of outcomes, we conducted sensitivity analyses by assessing the effects of removing low-quality publications (Francey et al., 2012; Chang and Choi, 2014; Gu et al., 2015; Vona et al., 2015; Bademci et al., 2016; Mehta et al., 2016; Sommen et al., 2016; Baux et al., 2017; Zazo Seco et al., 2017; Cabanillas et al., 2018; Guan et al., 2018; Marková et al., 2018; Sheppard et al., 2018; Back et al., 2019; Budde et al., 2020; Downie et al., 2020; Kim et al., 2020; Safka Brozkova et al., 2020). The summary prevalence of DFNB16 in non-GJB2 HL patients was 3.98% (95% CI: 0.0260–0.0606, I2 = 70%, p < 0.01), which stabilized the findings in the range of that of crude analysis. The I2 and p-value also indicated substantial heterogeneity. Results from a funnel plot (Figure 3A) and Egger test (p = 0.0549, Figure 3B) indicate an insignificant level of publication bias.Open in a separate windowFigure 3(A) Funnel plot. (B) Egger test.Prevalence of Carrier STRC Mutation in Non-GJB2 Hearing Impaired Participants and Individuals With Normal HearingEleven studies presented monoallelic variants of the STRC gene in non-GJB2 HI participants, with carriers varying from 0.92% in Spain to 11.27% in China (Table 1). The pooled carrier prevalence in HI participants (non-GJB2) assessed by the random-effects model was 4.84% (95% CI: 0.0343–0.0680, I2 = 54%, Figure 4). Three studies showed the carrier of the STRC mutation among normal-hearing individuals (Table 1). The summary carrier prevalence in people with normal hearing was 1.36% (95% CI: 0.0025–0.0696, I2 = 90%, Figure 5) using a random-effects model.Open in a separate windowFigure 4Prevalence of carrier STRC mutation in non-GJB2 HI participants.Open in a separate windowFigure 5Prevalence of carrier STRC mutation in normal hearing people.Prevalence of DFNB16 Among Genetically Confirmed Cases (Non-GJB2)Twenty-eight studies described genetically confirmed patients (Supplementary Table 2). Twenty-four were included in the meta-analysis to estimate the prevalence of STRC mutations in genetically diagnosed patients (non-GJB2) because the sample sizes of those with genetic diagnoses in these publications were no <10 cases (Table 1). The prevalence achieved using the random-effects model was 11.10% (95% CI: 0.0716–0.1682, I2 = 85%, p < 0.01) in 1,610 GJB2-negative genetically confirmed cases (Figure 6). I2 and p-value indicated substantial heterogeneity. Meta-regression was applied to evaluate the source of heterogeneity, with five categorical moderators: region, study population, gene detection method, degree of HI, and grade of quality assessment. Significant values were not detected for region, study population, gene detection method, and quality assessment (p = 0.9596, 0.5827, 0.1221, 0.4449). The degree of HI accounted for 28.00% of the variance between studies (p = 0.0019, R2 = 28.00%). The subgroup by region is shown in Supplementary Figure 2A, where the highest was in the US at 20.48% (95% CI: 0.1277–0.3118), followed by Europe at 14.54% (95% CI: 0.0820–0.2448), Asia with 5.68% (95% CI: 0.0113–0.2402), and other regions at 3.69% (95% CI: 0.0080–0.1535). The estimated pooled prevalence in the mild–moderate HI group was 50.71% (95% CI: 0.2813–0.7300) and that of the other-HI group was 9.44% (95% CI: 0.0620–0.1412) (Supplementary Figure 2B). Sensitivity analyses were completed by assessing the effects of deleting low-quality studies (Chang and Choi, 2014; Bademci et al., 2016; Mehta et al., 2016; Sommen et al., 2016; Baux et al., 2017; Zazo Seco et al., 2017; Cabanillas et al., 2018; Guan et al., 2018; Sheppard et al., 2018; Budde et al., 2020; Downie et al., 2020; Kim et al., 2020; Safka Brozkova et al., 2020). The summary prevalence of DFNB16 in genetically confirmed (non-GJB2) HL patients was 9.63% (95% CI: 0.0558–0.1614, I2 = 80%, p < 0.01) in the sensitivity analysis and without apparent fluctuation. The I2 and p-value showed substantial heterogeneity.Open in a separate windowFigure 6Prevalence of DFNB16 among genetically confirmed cases (non-GJB2).Prevalence of Deafness–Infertility Syndrome in STRC-Associated Hearing ImpairmentTwelve studies provided information about homozygous deletion in the CATSPER2 gene (Supplementary Table 2). Six articles, including ≥10 DFNB16 patients, were chosen for meta-analysis (Table 1). The overall pooled DIS prevalence in DFNB16 was 36.75% (95% CI: 0.2122–0.5563, I2 = 80%) using a random-effects model among 201 individuals (Figure 7).Open in a separate windowFigure 7Prevalence of deafness–infertility syndrome (DIS) in DFNB16.Prevalence of Biallelic Deletions in DFNB16The types of mutations in STRC were described in 36 studies (Supplementary Table 2). Of these, we selected nine articles with sample sizes not smaller than 10 DFNB16 cases for meta-analysis (Table 1). Because data extracted from Yokota et al. (2019) had proportions equal to 1, we analyzed the raw data with double arcsine transformation in advance. The pooled prevalence of biallelic deletions in DFNB16 was 70.85% (95% CI: 0.5824–0.8213, I2 = 74%) with a random-effects model (Figure 8).Open in a separate windowFigure 8Prevalence of biallelic deletions in DFNB16.DiscussionThe classical two-step strategy for deafness genetic testing consists of GJB2/6 locus analysis and gene panel based on NGS technologies. Although most panels have the STRC gene to detect SNVs or small indels, it is challenging for the NGS dataset to accurately detect CNVs in STRC, and even more challenging to detect CATSPER2 (Yokota et al., 2019). Considering the high prevalence of DFNB16 in genetically confirmed cases (11.10%), especially in the mild–moderate HI subgroup (50.71%), and biallelic CNVs in DFNB16 (70.85%), we consider that CNV detection of STRC should be accompanied by panel testing in case of misdiagnosis. Furthermore, males with DFNB16 should be advised about CATSPER2 gene sequencing because the DIS prevalence in DFNB16 was 36.75%. This is essential information that should be considered during genetic counseling.Different multistep strategies have been implemented for genetic exploration of HL. Valuable data were generated and screened in our study, and information should be extracted according to the following three aspects to make outcomes more reliable: First, as far as possible, consanguineous individuals should be merged into families. For instance, Lebeko et al. (2016) included 26 individuals from 10 GJB2-negative families, and the DFNB16 proportion was based on 10 families rather than patients. Although Mehta et al. (Mehta et al., 2016) did not describe consanguinity precisely, we did not omit the study from the analysis because it offered a large sample with the number of families marginally less than individuals. Second, apart from deletions and gene-pseudogene conversions, we also identified heterozygous duplications as monoallelic mutations, although there was no evidence of whether the duplications were pathogenic or had any effect on phenotypes (Yokota et al., 2019). At present, no patient has been diagnosed with biallelic duplications. Variations in pseudogenes that mutated into an inactive form and SNVs classified as non-pathogenic or benign were excluded for pooling prevalence. Third, when we estimated the prevalence of DFNB16 in genetically confirmed cases (non-GJB2), DIS in DFNB16, and biallelic deletions in STRC-associated HI patients, we removed studies with probands <10, which accords with the sample size exclusion criteria mentioned. From databases and references, only Cada et al. (2019) and Markova et al. (2020) showed more than 10 DFNB16 sample sizes for clinical features of DFNB16. However, we rejected these studies because it was unclear whether the data presented were for all the original patients or only the cases selected after qualified audiological examination was completed. There were no other eligible articles to add.When separating by HI degree, the prevalence of DFNB16 in non-GJB2 patients was significantly higher in the mild–moderate group (14.36%) than the other-HI group (3.67%) whose degree of HI was unclear or mixed. In the same way, the prevalence of DFNB16 in genetically confirmed cases (non-GJB2) was significantly higher in the mild–moderate group (50.71%) compared with the other-HI group (9.40%). Our results emphasized that STRC is a primary contributor to mild–moderate HI. This conclusion has also been documented in previous research (Francey et al., 2012; Yokota et al., 2019; Kim et al., 2020).Our data show that diallelic CNVs (mainly deletions) are an extreme factor in STRC gene mutations and are probably accompanied by homozygous deletions in CATSPER2 gene (36.75%) simultaneously. Given that STRC CNVs might be ignored in studies using NGS HL panels, screening techniques that contain CNV detection of STRC and CATSPER2 are recommended for patients before NGS analyses, especially in patients with bilateral mild-to-moderate HI (Plevova et al., 2017). Males with DIS will be deaf and infertile, and this is crucial information that should be realized during genetic counseling (Yokota et al., 2019). Females who inherit homozygous STRC-CATSPER2 deletions will only be deaf (Hildebrand et al., 2009), but CATSPER2 CNVs in women should also be taken seriously, not only to identify the etiology in probands but also to predict and prevent the disability in the next generation.There are some limitations to this meta-analysis. First, studies of the prevalence of STRC-related patients were available from only 16 countries, and data were not equally distributed. There were insufficient publications to provide adequate information for some continents. For example, in Africa, data were derived exclusively from Cameroon and Egypt. There were only five studies from developing countries, likely due to limited medical recording systems and medical care linked to possible under-recognition and late diagnosis of this disease. Second, the study designs and population covered in the included studies varied from hospital-based studies to national research. Investigation of DFNB16 in different populations and settings is urgently needed. Moreover, sample sizes of research studies need to be expanded, and more funding will be required for large-scale studies. Third, there is no uniform detection method for STRC variations. Information about STRC CNVs, monoallelic mutation, or CATSPERS2 deletions was ignored in some studies, affecting our confidence in prevalence assessment. The screening of CNVs could be impacted by different CNV detection methods, such as NGS or SNP array, and the proportion of STRC mutations may be found to be higher if effective strategies are applied (Yokota et al., 2019).In conclusion, we undertook the first meta-analysis to demonstrate that DFNB16 plays a crucial role in mild-to-moderate ARNSHL. The findings also emphasize the significance of detecting copy number variations of the STRC gene.Data Availability StatementThe original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.Author ContributionsSH conducted literature searches and data extraction and wrote the manuscript. DZ conducted literature searches and data extraction. YG and ZF reviewed the results. GG determined the final outcome, and wrote and checked the manuscript. All authors contributed to the article and approved the submitted version.Conflict of InterestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's NoteAll claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Supplementary MaterialThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.707845/full#supplementary-materialClick here for additional data file.(1.0M, docx)Click here for additional data file.(33K, docx)Click here for additional data file.(92K, doc)Click here for additional data file.(92K, doc)ReferencesAmr S. S., Murphy E., Duffy E., Niazi R., Balciuniene J., Luo M., et al.. (2018). Allele-specific droplet digital PCR combined with a next-generation sequencing-based algorithm for diagnostic copy number analysis in genes with high homology: proof of concept using Stereocilin. Clin. Chem. 64, 705–714. 10.1373/clinchem.2017.280685 [PubMed] [CrossRef] [Google Scholar]Back D., Shehata-Dieler W., Vona B., Hofrichter M. A. H., Schroeder J., Haaf T., et al.. (2019). Phenotypic characterization of DFNB16-associated hearing loss. Otol. Neurotol. 40, e48–e55. 10.1097/MAO.0000000000002059 [PubMed] [CrossRef] [Google Scholar]Bademci G., Foster J., Mahdieh N., Bonyadi M., Duman D., Cengiz F. B., et al.. (2016). Comprehensive analysis via exome sequencing uncovers genetic etiology in autosomal recessive nonsyndromic deafness in a large multiethnic cohort. Genet. Med. 18, 364–371. 10.1038/gim.2015.89 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Baux D., Vaché C., Blanchet C., Willems M., Baudoin C., Moclyn M., et al.. (2017). Combined genetic approaches yield a 48% diagnostic rate in a large cohort of French hearing-impaired patients. Sci. Rep. 7:16783. 10.1038/s41598-017-16846-9 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Brownstein Z., Gulsuner S., Walsh T., Martins F. T. A., Taiber S., Isakov O., et al.. (2020). Spectrum of genes for inherited hearing loss in the Israeli Jewish population, including the novel human deafness gene ATOH1. Clin. Genet. 98, 353–364. 10.1111/cge.13817 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Budde B. S., Aly M. A., Mohamed M. R., Bre,ß A, Altmüller J., Motameny S., et al.. (2020). Comprehensive molecular analysis of 61 Egyptian families with hereditary non-syndromic hearing loss. Clin. Genet. 98, 32–42. 10.1111/cge.13754 [PubMed] [CrossRef] [Google Scholar]Cabanillas R., Diñeiro M., Cifuentes G. A., Castillo D., Pruneda P. C., Álvarez R., et al.. (2018). Comprehensive genomic diagnosis of non-syndromic and syndromic hereditary hearing loss in Spanish patients. BMC Med. Genomics. 11:58. 10.1186/s12920-018-0375-5 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Cada Z, Šafka BroŽková D., Balatková Z., Plevová P., Rašková D., Laštuvková J., et al.. (2019). Moderate sensorineural hearing loss is typical for DFNB16 caused by various types of mutations affecting the STRC gene. Eur. Arch. Otorhinolaryngol. 276, 3353–3358. 10.1007/s00405-019-05649-5 [PubMed] [CrossRef] [Google Scholar]Chang M. Y., Choi B. Y. (2014). Strategy for the customized mass screening of genetic sensorineural hearing loss in Koreans. Korean J Audiol. 18, 45–49. 10.7874/kja.2014.18.2.45 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Costales M., Diñeiro M., Cifuentes G. A., Capín R., Otero A., Viejo-Díaz M., et al.. (2020). Clinical utility of next-generation sequencing in the aetiological diagnosis of sensorineural hearing loss in a Childhood Hearing Loss Unit. Acta Otorrinolaringol. Esp. 71, 166–174. 10.1016/j.otoeng.2019.05.005 [PubMed] [CrossRef] [Google Scholar]Downie L., Halliday J., Burt R., Lunke S., Lynch E., Martyn M., et al.. (2020). Exome sequencing in infants with congenital hearing impairment: a population-based cohort study. Eur. J. Hum. Genet. 28, 587–596. 10.1038/s41431-019-0553-8 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Francey L. J., Conlin L. K., Kadesch H. E., Clark D., Berrodin D., Sun Y., et al.. (2012). Genome-wide SNP genotyping identifies the Stereocilin (STRC) gene as a major contributor to pediatric bilateral sensorineural hearing impairment. Am. J. Med. Genet. A 158A, 298–308. 10.1002/ajmg.a.34391 [PMC free article] [PubMed] [CrossRef] [Google Scholar]García-García G., Berzal-Serrano A., García-Díaz P., Villanova-Aparisi R., Juárez-Rodríguez S., de Paula-Vernetta C., et al.. (2020). Improving the management of patients with hearing loss by the implementation of an NGS panel in clinical practice. Genes (Basel) 11:1467. 10.3390/genes11121467 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Gu X., Guo L., Ji H., Sun S., Chai R., Wang L., et al.. (2015). Genetic testing for sporadic hearing loss using targeted massively parallel sequencing identifies 10 novel mutations. Clin. Genet. 87, 588–593. 10.1111/cge.12431 [PubMed] [CrossRef] [Google Scholar]Guan Q., Balciuniene J., Cao K., Fan Z., Biswas S., Wilkens A., et al.. (2018). AUDIOME: a tiered exome sequencing-based comprehensive gene panel for the diagnosis of heterogeneous nonsyndromic sensorineural hearing loss. Genet. Med. 20, 1600–1608. 10.1038/gim.2018.48 [PubMed] [CrossRef] [Google Scholar]Hildebrand M. S., Avenarius M. R., Smith R. J. H. (2009). CATSPER-related male infertility, in GeneReviews®, eds Adam M. P. , Ardinger HH H. H. , Pagon R. A. , Wallace S. E. , Bean L. J. H , Mirzaa G. , Amemiya A. (Seattle, WA: University of Washington; ), 1993–2021. [Google Scholar]Hoy D., Brooks P., Woolf A., Blyth F., March L., Bain C., et al.. (2012). Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J. Clin. Epidemiol. 65, 934–939. 10.1016/j.jclinepi.2011.11.014 [PubMed] [CrossRef] [Google Scholar]Ito T., Kawashima Y., Fujikawa T., Honda K., Makabe A., Kitamura K., et al.. (2019). Rapid screening of copy number variations in STRC by droplet digital PCR in patients with mild-to-moderate hearing loss. Hum. Genome Var. 30:41. 10.1038/s41439-019-0075-5 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Ji H., Lu J., Wang J., Li H., Lin X. (2014). Combined examination of sequence and copy number variations in human deafness genes improves diagnosis for cases of genetic deafness. BMC Ear Nose Throat Disord. 14:9. 10.1186/1472-6815-14-9 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kannan-Sundhari A., Yan D., Saeidi K., Sahebalzamani A., Blanton S. H., Liu X. Z. (2020). Screening consanguineous families for hearing loss using the MiamiOtoGenes panel. Genet. Test. Mol. Biomarkers

24, 674–680. 10.1089/gtmb.2020.0153 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Kim B. J., Oh D. Y., Han J. H., Oh J., Kim M. Y., Park H. R., et al.. (2020). Significant Mendelian genetic contribution to pediatric mild-to-moderate hearing loss and its comprehensive diagnostic approach. Genet. Med. 22, 1119–1128. 10.1038/s41436-020-0774-9 [PubMed] [CrossRef] [Google Scholar]Lebeko K., Sloan-Heggen C. M., Noubiap J. J., Dandara C., Kolbe D. L., Ephraim S. S., et al.. (2016). Targeted genomic enrichment and massively parallel sequencing identifies novel nonsyndromic hearing impairment pathogenic variants in Cameroonian families. Clin. Genet. 90, 288–290. 10.1111/cge.12799 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Lipsey M., Wilson D. B. (2000). Practical Meta-Analysis. London: SAGE Publications. [Google Scholar]Mandelker D., Amr S. S., Pugh T., Gowrisankar S., Shakhbatyan R., Duffy E., et al.. (2014). Comprehensive diagnostic testing for stereocilin: an approach for analyzing medically important genes with high homology. J. Mol. Diagn. 16, 639–647. 10.1016/j.jmoldx.2014.06.003 [PubMed] [CrossRef] [Google Scholar]Marková S. P., BroŽková D. Š., Laššuthová P., Mészárosová A., Krutová M., Neupauerová J., et al.. (2018). STRC gene mutations, mainly large deletions, are a very important cause of early-onset hereditary hearing loss in the Czech population. Genet. Test. Mol. Biomarkers 22, 127–134. 10.1089/gtmb.2017.0155 [PubMed] [CrossRef] [Google Scholar]Markova T. G., Alekseeva N. N., Mironovich O. L., Galeeva N. M., Lalayants M. R., Bliznetz E. A., et al.. (2020). Clinical features of hearing loss caused by STRC gene deletions/mutations in Russian population. Int. J. Pediatr. Otorhinolaryngol. 138:110247. 10.1016/j.ijporl.2020.110247 [PubMed] [CrossRef] [Google Scholar]Mehta D., Noon S. E., Schwartz E., Wilkens A., Bedoukian E. C., Scarano I., et al.. (2016). Outcomes of evaluation and testing of 660 individuals with hearing loss in a pediatric genetics of hearing loss clinic. Am. J. Med. Genet. A 170, 2523–2530. 10.1002/ajmg.a.37855 [PubMed] [CrossRef] [Google Scholar]Moher D., Liberati A., Tetzlaff J., Altman D. J., PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.

21:e1000097. 10.1371/journal.pmed.1000097 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Morgan A., Lenarduzzi S., Cappellani S., Pecile V., Morgutti M., Orzan E., et al.. (2018). Genomic studies in a large cohort of hearing impaired Italian patients revealed several new alleles, a rare case of uniparental disomy (UPD) and the importance to search for copy number variations. Front. Genet. 9:681. 10.3389/fgene.2018.00681 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Morgan A., Lenarduzzi S., Spedicati B., Cattaruzzi E., Murru F. M., Pelliccione G., et al.. (2020). Lights and shadows in the genetics of syndromic and non-syndromic hearing loss in the Italian population. Genes (Basel) 22:1237. 10.3390/genes11111237 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Moteki H., Azaiez H., Booth K. T., Shearer A. E., Sloan C. M., Kolbe D. L., et al.. (2016). Comprehensive genetic testing with ethnic-specific filtering by allele frequency in a Japanese hearing-loss population. Clin. Genet. 89, 466–472. 10.1111/cge.12677 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Plevova P., Paprskarova M., Tvrda P., Turska P., Slavkovsky R., Mrazkova E. (2017). STRC deletion is a frequent cause of slight to moderate congenital hearing impairment in the Czech Republic. Otol. Neurotol. 38, e393–e400. 10.1097/MAO.0000000000001571 [PubMed] [CrossRef] [Google Scholar]Safka Brozkova D., Poisson Marková S., Mészárosová A. U., Jenčík J., Cejnová V., Cada Z., et al.. (2020). Spectrum and frequencies of non GJB2 gene mutations in Czech patients with early non-syndromic hearing loss detected by gene panel NGS and whole-exome sequencing. Clin. Genet. 98, 548–554. 10.1111/cge.13839 [PubMed] [CrossRef] [Google Scholar]Schrauwen I., Sommen M., Corneveaux J. J., Reiman R. A., Hackett N. J., Claes C., et al.. (2013). A sensitive and specific diagnostic test for hearing loss using a microdroplet PCR-based approach and next generation sequencing. Am. J. Med. Genet. A 161A, 145–152. 10.1002/ajmg.a.35737 [PubMed] [CrossRef] [Google Scholar]Shearer A. E., Black-Ziegelbein E. A., Hildebrand M. S., Eppsteiner R. W., Ravi H., Joshi S., et al.. (2013). Advancing genetic testing for deafness with genomic technology. J. Med. Genet. 50, 627–634. 10.1136/jmedgenet-2013-101749 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Shearer A. E., Kolbe D. L., Azaiez H., Sloan C. M., Frees K. L., et al.. (2014). Copy number variants are a common cause of non-syndromic hearing loss. Genome Med. 6:37. 10.1186/gm554 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sheffield A. M., Smith R. J. H. (2019). The epidemiology of deafness. Cold Spring Harb. Perspect. Med. 9:a033258. 10.1101/cshperspect.a033258 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sheppard S., Biswas S., Li M. H., Jayaraman V., Slack I., Romasko E. J., et al.. (2018). Utility and limitations of exome sequencing as a genetic diagnostic tool for children with hearing loss. Genet. Med. 20, 1663–1676. 10.1038/s41436-018-0004-x [PMC free article] [PubMed] [CrossRef] [Google Scholar]Shi L., Bai Y., Kharbutli Y., Oza A. M., Amr S. S., Edelmann L., et al.. (2019). Prenatal cytogenomic identification and molecular refinement of compound heterozygous STRC deletion breakpoints. Mol. Genet. Genomic Med. 7:e806. 10.1002/mgg3.806 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sloan-Heggen C. M., Babanejad M., Beheshtian M., Simpson A. C., Booth K. T., Ardalani F., et al.. (2015). Characterising the spectrum of autosomal recessive hereditary hearing loss in Iran. J. Med. Genet. 52, 823–829. 10.1136/jmedgenet-2015-103389 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sloan-Heggen C. M., Bierer A. O., Shearer A. E., Kolbe D. L., Nishimura C. J., Frees K. L., et al.. (2016). Comprehensive genetic testing in the clinical evaluation of 1119 patients with hearing loss. Hum. Genet. 135, 441–450. 10.1007/s00439-016-1648-8 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Sommen M., Schrauwen I., Vandeweyer G., Boeckx N., Corneveaux J. J., van den Ende J., et al.. (2016). DNA diagnostics of hereditary hearing loss: a targeted resequencing approach combined with a mutation classification system. Hum. Mutat. 37, 812–819. 10.1002/humu.22999 [PubMed] [CrossRef] [Google Scholar]Verpy E., Leibovici M., Michalski N., Goodyear R. J., Houdon C., Weil D., et al.. (2011). Stereocilin connects outer hair cell stereocilia to one another and to the tectorial membrane. J. Comp. Neurol. 519, 194–210. 10.1002/cne.22509 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Verpy E., Masmoudi S., Zwaenepoel I., Leibovici M., Hutchin T. P., Del Castillo I., et al.. (2001). Mutations in a new gene encoding a protein of the hair bundle cause nonsyndromic deafness at the DFNB16 locus. Nat. Genet. 29, 345–349. 10.1038/ng726 [PubMed] [CrossRef] [Google Scholar]Verpy E., Weil D., Leibovici M., Goodyear R. J., Hamard G., Houdon C., et al.. (2008). Stereocilin-deficient mice reveal the origin of cochlear waveform distortions. Nature 456, 255–258. 10.1038/nature07380 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Vona B., Hofrichter M. A., Neuner C., Schröder J., Gehrig A., Hennermann J. B., et al.. (2015). DFNB16 is a frequent cause of congenital hearing impairment: implementation of STRC mutation analysis in routine diagnostics. Clin. Genet. 87, 49–55. 10.1111/cge.12332 [PMC free article] [PubMed] [CrossRef] [Google Scholar]World Health Organization (2021). Deafness and Hearing Loss. Available online at: https://www.who.int/health-topics/hearing-loss#tab=tab_1 (accessed April 15, 2021).Yokota Y., Moteki H., Nishio S. Y., Yamaguchi T., Wakui K., Kobayashi Y., et al.. (2019). Frequency and clinical features of hearing loss caused by STRC deletions. Sci. Rep. 9:4408. 10.1038/s41598-019-40586-7 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Zazo Seco C., Wesdorp M., Feenstra I., Pfundt R., Hehir-Kwa J. Y., Lelieveld S. H., et al.. (2017). The diagnostic yield of whole-exome sequencing targeting a gene panel for hearing impairment in The Netherlands. Eur. J. Hum. Genet. 25, 308–314. 10.1038/ejhg.2016.182 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Zhang Y., Malekpour M., Al-Madani N., Kahrizi K., Zanganeh M., Lohr N. J., et al.. (2007). Sensorineural deafness and male infertility: a contiguous gene deletion syndrome. J. Med. Genet. 44, 233–240. 10.1136/jmg.2006.045765 [PMC free article] [PubMed] [CrossRef] [Google Scholar]Articles from Frontiers in Genetics are provided here courtesy of Frontiers Media SA

Other Formats

PDF (3.4M)

Actions

Cite

Collections

Add to Collections

Create a new collection

Add to an existing collection

Name your collection:

Name must be less than characters

Choose a collection:

Unable to load your collection due to an error

Please try again

Add

Cancel

Share

 

 

 

Permalink

Copy

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

[x]

Cite

Copy

Download .nbib

.nbib

Format:

AMA

APA

MLA

NLM

Follow NCBI

Twitter

Facebook

LinkedIn

GitHub

Connect with NLM

SM-Twitter

SM-Facebook

SM-Youtube

National Library of Medicine

8600 Rockville Pike

Bethesda, MD 20894

Web Policies

FOIA

HHS Vulnerability Disclosure

Help

Accessibility

Careers

NLM

NIH

HHS

USA.gov

St.Rose Catholic School | Public Portal

St.Rose Catholic School | Public Portal

S.R.C.S. Web Portal v 1.0

  +63 909 182 9064

Students 

Alumni 

Parents 

Faculty 

Staff 

Toggle Navigation

ACADEMIC

ACADEMICS

BASIC EDUCATION

It covers... read more

JUNIOR HIGH SCHOOL

Junior High School covers... read more

SENIOR HIGH SCHOOL

Accountancy, business... read more

ADMIN

ADMINISTRATIVE SECTION

ORGANIZATION

Board of Trustees

Principals Office

Registrars Office

Accounting Office

Guidance Office

Clinic

Students Council

FACULTY & STAFF

Pre Elem Department

Elementary Department

Junior High School

Senior High School

SCHOOL CALENDAR

January - February

March - April

May- June

July - August

September- October

November - December

ALUMNI

DATA PRIVACY

S.R.C.S. Observes strict guidelines in securing our students information may it be manual or systematic in nature.. read more (Data Privacy Act of 2012)

ADMISSION

  ONLINE ADMISSION

SRCS online application for S.Y. 2020-2021 is now....Read more

NEWS

LATEST NEWS

ANNOUNCEMENT

List of Email with failed delivery..

School Resolutions

n19 COVID Update

GALLERY

JS Prom Night

Recreational Field Trip

Moving-Up & Graduation Day

SERVICES

SERVICES AND FORMS

SERVICES

Online Document Request

DOWNLOADABLE FORMS

Admission Form

Proxy-Request Form

FAQs  

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

St. Rose Catholic School, Inc.

Learn more ...

Student Registrations

Parent Registrations

Document Request

S.R.C.S.

Academic

Basic Education

Junior High School

Senior High School

Admin

Organization

Faculty

School Calendar

Admission

News

Announcement

Gallery

Services

Document Request

Downloadable Forms

FAQ's

SICT

CONCS Concepcion Catholic School

Dizon St., San Nicolas, Concepcion, Tarlac

09981656048

GCS Gerona Catholic School

Gerona, Tarlac

()

SNASto. Nino Academy Bamban

Bamban, Tarlac

045 4931232

VCS

SACTS

DCT Domican College of Tarlac Dizon St., San Sto. Rosario St., Capas, Tarlac

(045 925-0519)

OLRS Our Lady of Ransom Catholic School Manga 1, Matatalaib Tarlac City

(045) 925 5778

CAMCSCamiling Catholic School Camiling, Tarlac

()

SSCS San Sebastian Cathedral School

Tarlac City

(045) 982 4232

MCSMoncada CatholicSchool

Tarlac City

0948 488 7801

Follow us on

Contact US

srcs_srcs@yahoo.com

  +63 909 182 9064

Contact US

srcs_srcs@yahoo.com

  +63 909 182 9064

New Enrollees

Check your verification code on your email, and wait for your phone call interview..

All Students

All students are advised to use a valid email address upon registration

Payments

Ask for payment appointment on your Student Portal under Payments Section

Tuition Fee

No tuition fee increase this S.Y. 2022-2023, and check your SRCS Note Portal for your initial registration fee..

Scholarships

We offer ESC, QVR and other scholarships.

Programs

K-12 Programs, STEM , HUMSS, ABM, TechVoc(ICT, HE)

Faculty

The best faculties/professors to guide you!!

Facilities

We provides our students the best innovative and technological tools for their education.

© THE SRCS WEBSITE v 1.0

(c) 2018-2023

Login

Email -

User Password

Log-In

Forgot password /

Register Now using (IG)

Close Login

Just a moment...

a moment...Enable JavaScript and cookies to continue

TEAM STRC

TEAM STRC

Skip to content

Enter using password

Enter store using password:

Your password

Enter

Are you the store owner? Log in here

Re-Opening Soon

We will be closed starting 2/13/2024 in preparation for our new website launch 3/31/2024

Email

This shop will be powered by

Are you the store owner? Log in here

Opens in a new window.